Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi Puig

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Blood Cancer Discovery|March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancersCarmen González, Juan-Jose Garces, Hector Gracia, et al.
Leukemia|June 2, 2020
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaJuan-José Garcés, Gabriel Bretones, Leire Burgos, et al.
Leukemia|December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosisNoemi Puig, Bruno Paiva, Marta Lasa, et al.
Leukemia|March 24, 2020
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosisIsabel Cuenca, Daniel Alameda, Beatriz Sanchez-Vega, et al.
Future Oncology (London, England)|March 26, 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myelomaRoman Hájek, Jiří Minařík, Jan Straub, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Science Advances|January 19, 2022
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphomaSara Rodriguez, Jon Celay, Ibai Goicoechea, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Blood Advances|March 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO studyIrene Dogliotti, Cristina Jiménez, Veronica Peri, et al.
Blood|April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myelomaCatarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Blood Cancer Discovery|March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancersCarmen González, Juan-Jose Garces, Hector Gracia, et al.
Leukemia|June 2, 2020
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaJuan-José Garcés, Gabriel Bretones, Leire Burgos, et al.
Leukemia|December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosisNoemi Puig, Bruno Paiva, Marta Lasa, et al.
Leukemia|March 24, 2020
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosisIsabel Cuenca, Daniel Alameda, Beatriz Sanchez-Vega, et al.
Future Oncology (London, England)|March 26, 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myelomaRoman Hájek, Jiří Minařík, Jan Straub, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Science Advances|January 19, 2022
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphomaSara Rodriguez, Jon Celay, Ibai Goicoechea, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Blood Advances|March 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO studyIrene Dogliotti, Cristina Jiménez, Veronica Peri, et al.
Blood|April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myelomaCatarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
Pageof 9